Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.

ABSTRACT:

Background

Data on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D-cirrhosis) are limited.

Methods

In this prospective multicenter study, adult participants with C-cirrhosis and D-cirrhosis were enrolled and received two doses of inactivated whole-virion COVID-19 vaccines. Adverse events were recorded within 14 days after any dose of vaccination, and serum samples of enrolled patients were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose. Risk factors for negative neutralizing antibody were analyzed.

Results

In total, 553 patients were enrolled from 15 centers in China, including 388 and 165 patients with C-cirrhosis

SUBMITTER: Wang J 

PROVIDER: S-EPMC8995697 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature